Early low-dose hydrocortisone,
does it really help with Increased survival without bronchopulmonary dysplasia in extremely preterm infants?
research showsThe grade is B with 72 points. PREMILOC randomized 523 infants across 21 French NICUs and analyzed 521 after two consent withdrawals under its prespecified intention-to-treat approach. Survival without bronchopulmonary dysplasia at 36 weeks was 153/255 (60%) versus 136/266 (51%), adjusted OR 1.48 (95% CI 1.02–2.16), an absolute 9-point benefit and NNT of 12. The trial stopped at 523 of a planned 786 infants because of financial and technical support limitations, and the planned analysis was adjusted accordingly.
ads claimThe evidence applies to a specific intravenous regimen during the first ten days in NICU infants born at 24 weeks 0 days to 27 weeks 6 days. It cannot be generalized to healthy newborns or unsupervised steroid use.
Useful facts when choosing a product
- The prespecified intention-to-treat analysis included 521 of 523 randomized infants after one consent withdrawal in each group.
- The trial stopped at 523 of a planned 786 infants because of financial and technical support limitations.
- A late-onset sepsis signal appeared in the 24–25-week subgroup.
What the research actually shows
This was a double-blind placebo-controlled sequential trial at 21 French NICUs. Infants were randomly assigned 1:1 through a secure study website, and investigators, parents, and patients were masked to allocation. The prespecified primary analysis was based on intention to treat, excluding only one consent withdrawal per group. Survival without BPD at 36 weeks' postmenstrual age matched the registered primary outcome. Planned enrollment was 786, but financial and technical support limitations stopped the trial at 523 and the planned analysis was adjusted accordingly.
Why this is classified as B (72)
Random 1:1 assignment through a secure study website, masking of investigators, parents, and patients, prespecified intention-to-treat analysis excluding only one consent withdrawal per group, and the registration-consistent 36-week BPD-free survival endpoint were documented. Even with these four safeguards, stopping for financial and technical support limitations at 523 of a planned 786 is one B1 limitation, giving B with 72 points.
Counterpoint. The late-sepsis increase in the most immature 24–25-week subgroup requires confirmation and close monitoring.
Rejudgment record. Cross-check applied — Random assignment through a secure study website, masking of investigators, parents, and patients, prespecified intention-to-treat analysis excluding only one consent withdrawal per group, and a registration-consistent primary endpoint were documented, but financial and technical support limitations stopped enrollment at 523 of a planned 786 and the analysis was adjusted
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Increased survival without BPD at 36 weeks | B | Rates were 60% versus 51%, an absolute 9-point difference. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Double-blind placebo-controlled sequential randomized trial at 21 NICUs; stopped early for support limitations | 266 | Assistance Publique-Hôpitaux de Paris; no corporate funding or in-kind support identified | Survival without bronchopulmonary dysplasia at 36 weeks | 153/255 (60%) versus 136/266 (51%), adjusted OR 1.48 (95% CI 1.02–2.16), absolute difference +9 points, NNT 12; late sepsis in the 24–25-week subgroup was 40% versus 23%, sub-HR 1.87 (1.09–3.21) | Single public-hospital-sponsored trial; stopped at 523 of a planned 786 |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Early low-dose hydrocortisone x BPD-free survival in extremely preterm infants — Evidence Grade B·72. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/general/early-low-dose-hydrocortisone-extremely-preterm-bpd-free-survival/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.